The Treatment Options and Clinical Significance of Immune Thrombocytopenia Patients with Splanchnic Vein Thrombosis as the Initial Manifestation.
10.19746/j.cnki.issn.1009-2137.2021.03.037
- Author:
Lin LIN
1
;
Ran YANG
2
;
Yu WU
2
;
Hui HUANG
3
;
Ou JI
1
;
Qun SHEN
4
Author Information
1. Department of Hematology, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province, China,The First Clinical College of Nanjing University of Chinese Medicine, Nanjing 210046, Jiangsu Province, China.
2. Department of Hematology, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province, China.
3. Department of Ultrasound Medicine, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province, China.
4. Department of Hematology, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province, China,E-mail: shenqun1016@163.com.
- Publication Type:Journal Article
- MeSH:
Aged, 80 and over;
Anticoagulants/therapeutic use*;
Heparin, Low-Molecular-Weight;
Humans;
Male;
Purpura, Thrombocytopenic, Idiopathic/complications*;
Splanchnic Circulation;
Venous Thrombosis
- From:
Journal of Experimental Hematology
2021;29(3):887-892
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the causes, treatment options and outcomes of immune thrombocytopenia (ITP) patients with splanchnic venous thrombosis (SVT).
METHODS:The clinical diagnosis, treatment and outcomes data of one 26-year-old male ITP patient with SVT as initial manifestation were collected. The possible causes and treatment options of the patients were discussed through literatures review.
RESULTS:The result of blood routine tests of the patient showed that Plt（17-38）×10
CONCLUSION:ITP combined with large scale of SVT is rare, and it is difficult to cure. It should be pay more attention to the possible thrombosis risk triggered by a transiently increased EOS in the blood stream. Promptly etiological treatment and the balance between anticoagulant therapy and bleeding risks should be taken in clinical practice.
